Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Endocyte

Drug Profile

Research programme: cancer therapeutics - Endocyte

Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC 2629; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682

Latest Information Update: 31 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Depsipeptides; Doxorubicins; Drug conjugates; Folic acids; Oligopeptides; Small molecules; Taxanes
  • Mechanism of Action Folate receptor 1 antagonists; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 09 Feb 2018 EC 2629 is still in non-clinical development for Solid tumours in USA (Endocyte website, Feb 2018)
  • 09 Feb 2018 EC 2629 is available for licensing as of 09 Feb 2017. http://endocyte.com/technology/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top